Streptokinase is approved for the treatment of which of the following conditions?

Streptokinase is a thrombolytic agent that is primarily used in the treatment of acute myocardial infarction (heart attack) and in the management of certain thromboembolic conditions. While chronic hypertension, asthma attacks, and diabetes management pertain to different therapeutic categories and do not involve the direct clearance of clotting factors or thrombus, streptokinase’s role is centered on dissolving blood clots.

Peripheral vascular disease involves inadequate blood flow to the limbs due to vascular occlusions, often requiring interventions aimed at improving circulation. While streptokinase specifically addresses clot-related issues, its use may still play a role in specific acute scenarios related to peripheral arterial occlusions or embolisms. This makes it relevant in the context of peripheral vascular disease, as treating clots may help alleviate the symptoms or complications associated with this condition.

The other options refer to chronic conditions that do not typically require thrombolytic therapy, which is what streptokinase provides. Thus, peripheral vascular disease is the appropriate condition for which streptokinase is recognized, specifically when clot dissolution is clinically advantageous.